CEO transition positions Medifacts for growth and expansion
ROCKVILLE, MARYLAND (USA) / LANGENFELD, GERMANY– October 31, 2006 – Medifacts International, a global provider of clinical research and cardiac safety services, announced today that Michael E. Woehler, PhD has been named as the Company's new President and Chief Executive Officer.
Dr. Woehler has had more than 25 years of experience in leading global businesses in the life sciences and CRO industries. Most recently, he served as the Executive Vice President of PAREXEL International Corporation where he was responsible for the Worldwide Consulting, Medical Marketing Services and Clinical Pharmacology business, Corporate Services, and the Corporate Quality divisions. Dr. Woehler also served as PAREXEL's Senior Vice President and President of Clinical Research Services for four years where he managed 3000 employees worldwide.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.